KURA Stock Summary and Trading Ideas (Kura Oncology | NASDAQ:KURA)

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

Kura Oncology trades on the NASDAQ stock market under the symbol KURA.

As of October 8, 2026, KURA stock price declined to $10.48 with 770,053 million shares trading.

KURA has a beta of 1.41, meaning it tends to be more sensitive to market movements. KURA has a correlation of 0.09 to the broad based SPY ETF.

KURA has a market cap of $932.31 million. This is considered a Small Cap stock.

Last quarter Kura Oncology reported $21 million in Revenue and -$.77 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.11.

In the last 3 years, KURA traded as high as $24.17 and as low as $5.41.

The top ETF exchange traded funds that KURA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

KURA has underperformed the market in the last year with a price return of +11.1% while the SPY ETF gained +16.6%. KURA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -12.6% and -5.1%, respectively, while the SPY returned +3.6% and +0.6%, respectively.

KURA support price is $10.36 and resistance is $10.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KURA shares will trade within this expected range on the day.